Southwest Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a holding rating. The main reasons for the rating include: 1) Befotinib is expected to be rapidly dosed, and the first-line NDA of enzatinib has been accepted by the FDA; 2) the strategic cooperation has achieved remarkable results, and the ophthalmic indications of Heyuan Biorecombinant are worth looking forward to; 3) Early clinical progress is steady, and EGFR/C-MET dual antagonists have the potential to become a first-line treatment for EGFR-positive NSCLC. (Mainichi Keizai Shimbun)
西南证券4月22日发布研报称，给予贝达药业（300558.SZ）持有评级。评级理由主要包括：1）贝福替尼有望快速放量，恩莎替尼一线NDA获FDA受理；2）战略合作成果显著，禾元生物重组人白、伏美纳眼科适应症值得期待；3）早期临床稳步推进，EGFR/C-MET双抗联用贝福替尼有潜力成为EGFR阳性NSCLC一线治疗。（每日经济新闻）
Southwest Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a holding rating. The main reasons for the rating include: 1) Befotinib is expected to be rapidly dosed, and the first-line NDA of enzatinib
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.